Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant

NCT03497845 is registered in ClinicalTrials.gov with Biomedical Advanced Research and Development Authority as lead sponsor.

NCT NCT03497845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Lead sponsor
Biomedical Advanced Research and Development Authority
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2018
Completion date
November 19, 2019
Enrollment
720 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a virus, h5n1 subtype